Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
versican Double Nickase Plasmid (h): sc-401173-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- versican Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- versican Double Nickase Plasmid (h) and versican Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting VCAN. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: versican Antibody (4C5): sc-47769
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
versican Double Nickase Plasmid (h) | sc-401173-NIC | 20 µg | $410.00 | |||
versican Double Nickase Plasmid (h2) | sc-401173-NIC-2 | 20 µg | $410.00 |
Human VCAN encodes versican, a large chondroitin sulfate proteoglycan of the extracellular matrix that shapes pericellular architecture and regulates cell adhesion, migration, and proliferation through interactions with hyaluronan, integrins, and growth factor signaling. Versican contributes to tissue morphogenesis and wound repair and modulates mechanotransduction and inflammatory cell trafficking within stromal and vascular microenvironments. Altered VCAN expression or isoform balance has been linked to extracellular matrix remodeling programs implicated in fibrosis, atherosclerosis, and tumor-associated stroma, where it can influence invasion and immune infiltration. These features make VCAN a useful target for studying matrix-driven signaling, epithelial–mesenchymal dynamics, and cell–matrix crosstalk in human model systems.
versican Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the VCAN locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within VCAN. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt VCAN function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of VCAN-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.